Login
Open Demat Account
Open Demat A/C
Offerings
+
Research
Markets+
Talking Finance+
Support+
Media+
Partner Us+
Trade LoginReports LoginIFD Partner Login
Demo
Close Language Tab
Locate us
Languages
  • Home
  • Company Information
  • Natco Pharma Ltd
N
Natco Pharma Ltd Pharmaceuticals
₹ 973.15 +14.65 (1.53%)
  • NSE
  • BSE

Overview

  • BSE Code 524816
  • NSE Symbol NATCOPHARM
  • ISIN Demat INE987B01026
  • Book Value (₹) 409.46
  • Face Value (₹) 2.00
  • Market Cap (₹ Cr.) 18,536.08
  • P/E (TTM) 10.02
  • EPS (TTM) 103.31
  • Div Yield (%) 0.58

Performance

Today’s Low 957.70
Today’s High 985.15

973.15
52W Low 726.80
52W High 1,639.00

973.15
Open 963.15
Prev. Close 958.50
Volume 6,54,958.00

Corporate Actions

Natco Pharma Limited - Certificate under SEBI (Depositories and Participants) Regulations, 2018
Apr 17, 2025

Natco Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

About Natco Pharma Ltd

Journey of Natco Pharma Limited

Incorporated in 1981, Natco Pharma Limited is involved in the manufacturing and sale of pharmaceutical products.  The company was started in 1981 in Kothur, Mahaboobnagar district, Telangana. In 1986, they opened a parental manufacturing unit at Nagarjunasagar. In 1993, the company inaugurated a chemical division at Mekaguda. In 1995, Natco Trust originated as, and Natco merged three of the group companies with the parent company. In the same year, they went public and got listed on the Indian stock exchanges. In 1997, they opened the Natco Research Centre (NRC).  In 2003, the company made a strategic entry into the Oncology division and launched its flagship brand, Veenat. In 2006, Natco Pharma Limited established a finished dosage unit at Dehradun. In the next year, i.e., in 2007, they launched their first Abbreviated New Drug Application (ANDA) in the USA. They also gained complete control of Savemart Pharmacy in the USA. In 2009, the company established Natco Organics in Chennai, and in the same year, the company turnover touched $100 million. Between 2013 and 2014, the company established in Canada and Australia.  In 2016, Natco Pharma Limited sold Savemart Pharmacy in the USA. In 2017, they made a strategic entry into the Diabetology and Cardiology divisions. In 2018, they launched Teriflunomide, the company’s first generic version of oral tablets for multiple sclerosis in India. In 2019, they launched the crop health science division. In 2020, the company’s Vishakapatnam Formulation unit was approved by the US FDA. In the same year, Natco Pharma supplied COVID-19 treatment tablets, Chloroquine Phosphate tablets in the USA. In 2021, the company launched other drugs for Covid treatment. In 2022, Natco Pharma’s crop health science division launched agro products in India.  As of March 2023, Natco Pharma Limited has a presence in more than 50 countries and 465 scientists. They have 5 Finished Dosage Forms (FDF) manufacturing units, 2 Active Pharmaceutical Ingredients (API) manufacturing units, 2 R&D centres and 2 crop health sciences units. 

Business Segments of Natco Pharma Limited

The two primary business segments of the company are as follows: 
  • Pharmaceuticals:In this segment, the organization is involved in the development, manufacturing and marketing of FDF and APIs.
  • Agrochemicals:In this segment, the organization core priorityes on providing eco-friendly biopesticide products for farmers, thus contributing to sustainable farming.
As of March 31, 2023, a few of the subsidiaries of Natco Pharma Limited are as follows:
  • Natco Pharma Inc:This wholly-owned subsidiary of the organization is involved in the retail sale of prescription drugs and non-prescription medicines.
  • Natco Pharma Australia Pty Ltd:This wholly-owned subsidiary of the organization was established for the sale and distribution of pharmaceutical products in Australia.
  • Natco Pharma (Canada) Inc:This wholly-owned subsidiary of the organization was established for the sale and distribution of pharmaceutical products in Canada.

Key Personalities of Natco Pharma Limited

V.C. Nannapaneni, Managing Director V.C. Nannapaneni is the Managing Director of Natco Pharma Limited. He has more than 40 years of experience in the pharmaceutical sector. In addition to handling general management responsibilities, he supervises the New Drug Discovery program within the company.
Founded: 1981
Chairman: V C Nannapaneni
Managing Director: V C Nannapaneni
Address: Natco House, Road No 2 Banjara Hills, Hyderabad, Telangana, 500033,
HO Tel: 91-040-23547532